A modified citrus pectin Gal-3 inhibitor has been evaluated for effects markers of collagen metabolism in patients with hypertension in a proof-of-concept clinical trial for cardiac fibrosis.56 CSF-1 and MMP-12 inhibitors are currently being evaluated in clinical trials for non-HF conditions. This evidence concerns the gene CSF1 and hydrops fetalis.